Scientists at the Garvan Institute of Medical Research have identified a previously unrecognized flaw in the immune system that drives inflammation in mevalonate kinase deficiency (MKD). The findings, published in the journal Immunity, challenge 30 years of established medical thinking and suggest that existing medications could offer new hope for patients who do not respond to current therapies.
Natural Killer Cells Drive Inflammation
For decades, research into MKD focused on macrophages, immune cells that coordinate inflammatory defenses. Existing treatments target signals released by these cells. However, approximately half of patients do not respond adequately to these therapies. The new study reveals that natural killer (NK) cells, which normally help eliminate infected cells, are the primary drivers of the disorder.
In people with MKD, NK cells fail to mature properly. They struggle to destroy infected cells, which allows infections to spread. When these cells cannot kill their targets, they release large amounts of inflammatory signaling molecules. This process activates other parts of the immune system and triggers widespread inflammation.
Professor Mike Rogers, Lab Head at Garvan and senior author of the study, explained that the cells essentially misfire. The toxic granules inside NK cells remain trapped because the cells cannot release them. To compensate for this failure, the cells pump out interferon gamma, a powerful inflammatory signal. This signal activates other immune cells and causes the dangerous fever and inflammation seen in patients.
Experimental Treatment Shows Promise
The discovery has already guided an experimental treatment approach for a severely affected infant. Doctors at the Royal Children’s Hospital in Melbourne added baricitinib to the child’s existing treatment regimen. Baricitinib belongs to a class of medications known as JAK inhibitors, which interfere with signaling pathways used by the immune system.
After adding the medication, doctors observed an improvement in the child’s condition. Inflammatory flare-ups became less frequent, and severe inflammation affecting the gastrointestinal tract began to heal. While results from a single patient cannot establish whether the treatment will work more broadly, the improvement provides encouraging early evidence for a strategy that targets a different part of the inflammatory process.
Dr. Marcia Munoz, Group Leader in the Rogers Lab and lead researcher on the study, stated that the results represent a major change in how scientists understand the disease. She noted that the primary problem lies in NK cells rather than macrophages, as previously believed.
Broader Implications for Genetic Disorders
The researchers believe their findings provide a foundation for future clinical studies investigating JAK inhibitors and other medications that block interferon gamma activity in patients with MKD. This is particularly valuable for patients who have not benefited from standard treatments.
Researchers have introduced the term ‘prenylopathies’ to describe a family of genetic disorders involving the same metabolic pathway affected in MKD. Early findings suggest that these related diseases may share a similar underlying problem involving natural killer cells that fail to function properly and instead generate excessive inflammatory signals. If further studies confirm this connection, scientists may be able to identify common disease mechanisms and develop more targeted approaches to diagnosis and treatment across multiple disorders.
Professor Rogers emphasized that confirming this link could help end the diagnostic odyssey many patients endure for years or even decades before receiving effective treatment. The study highlights the importance of re-evaluating long-held assumptions in medical research to find new solutions for rare diseases.
Source: ScienceDaily

